Integrating Biology and Medicine for Scientific Excellence

Dr. Sophia L Bennett
School of Public Health University of Ottawa Ottawa, Canada

* Corresponding Author: **Dr. Sophia L Bennett**

Article Info

E-ISSN: 3107-7137
Volume: 02
Issue: 02
Received: 09-12-2025
Accepted: 07-02-2026
Published: 05-03-2026
Page No: 14-21

Abstract

Background: The integration of biology and medicine represents a foundational paradigm for achieving scientific excellence in the biomedical sciences. This convergence seeks to bridge the traditional divide between basic biological discovery and clinical application, creating a seamless continuum from molecular understanding to patient care.

Recent Advances: Significant progress has been made across multiple fronts. Advances in molecular and cellular biology—including genomics, transcriptomics, and multi-omics technologies—have provided unprecedented resolution into disease mechanisms. Systems biology and computational modeling enable the integration of complex datasets into predictive frameworks. CRISPR-based genome engineering and synthetic biology approaches are translating fundamental insights into novel therapeutics. In the clinical domain, precision medicine, immunotherapy, and regenerative medicine are demonstrating the power of biologically informed treatment strategies. Artificial intelligence and digital health platforms are accelerating the integration of biological knowledge into routine clinical decision-making.

Key Challenges: Despite these advances, fragmentation between basic and clinical research persists, impeded by differences in culture, funding mechanisms, and reward systems. Data interoperability barriers limit the integration of molecular and clinical datasets. Reproducibility concerns and research integrity challenges undermine confidence in translational findings. Disparities in access to advanced diagnostics and therapeutics perpetuate health inequities, both within and between nations.

Future Directions: The next decade will witness deeper convergence of biology with engineering, computational science, and data science. Integrated omics-driven healthcare systems will enable predictive, preventive, and personalized approaches to medicine. Strengthened pandemic preparedness and global health resilience will depend on sustained biological–medical integration. Achieving scientific excellence will require deliberate investment in interdisciplinary training, collaborative infrastructure, and governance frameworks that balance innovation with ethical responsibility.

Keywords: Translational Science; Precision Medicine; Genomics; Systems Biology; Immunotherapy; Artificial Intelligence; Interdisciplinary Research

1. Introduction

The integration of biology and medicine represents a conceptual framework in which fundamental understanding of living systems is deliberately and systematically applied to prevent, diagnose, and treat human disease. This integration is not merely the application of biological tools to medical problems, but rather a bidirectional exchange in which clinical insights inform basic biological questions and biological discoveries reshape clinical practice [1]. At its core, this paradigm recognises that scientific excellence in biomedicine requires seamless continuity from molecular mechanism to population health.

The historical evolution of translational science reveals a trajectory toward increasingly deliberate integration. The term 'translational research' emerged in the 1990s to describe the process of applying discoveries from basic science to clinical development, often conceptualised as 'bench to bedside' [2]. However, early formulations of this concept were criticised for their unidirectional nature, failing to capture the essential feedback from clinical observation to basic investigation. More sophisticated frameworks now emphasise the iterative, bidirectional nature of translation, recognising that clinical insights frequently generate fundamental questions that drive new cycles of discovery [3].

The importance of interdisciplinary integration for scientific excellence cannot be overstated. The most transformative advances in modern medicine have emerged from the convergence of disciplines: immunology and cancer biology giving rise to checkpoint inhibitors; genetics and chemistry enabling precision therapeutics; computational science and structural biology producing revolutionary protein structure prediction [4]. These successes demonstrate that scientific excellence is increasingly found at the interfaces between traditional fields, where diverse perspectives and methods combine to generate novel insights.

In advancing diagnostics, therapeutics, and public health, biological–medical integration plays an essential role. Molecular diagnostics based on genomic and proteomic biomarkers enable earlier and more precise disease detection. Targeted therapies informed by tumour biology improve outcomes while reducing toxicity. Population-level integration of genomic and environmental data supports risk stratification and preventive interventions [5]. The COVID-19 pandemic provided a powerful demonstration of integrated science in action, with fundamental research on viral biology, mRNA chemistry, and immunology combining to produce life-saving vaccines within months [6].

This review provides a comprehensive examination of the integration of biology and medicine for scientific excellence. It explores the biological foundations driving medical innovation, the clinical translation of these insights, the infrastructure required to support integration, and the ethical and societal considerations that must accompany progress. By synthesising recent advances and identifying persistent challenges, the review aims to articulate a vision for achieving scientific excellence through sustained biological–medical convergence.

2. Biological Foundations Driving Medical Innovation

The integration of biology and medicine rests upon a foundation of fundamental biological discovery. Advances in understanding the molecular and cellular basis of life continue to generate insights that transform medical practice. Advances in molecular and cellular biology have provided the conceptual framework for modern biomedicine. Elucidation of signalling pathways, cellular differentiation mechanisms, and intercellular communication networks has revealed the fundamental logic of physiological and pathological processes. Understanding of apoptosis, autophagy, and other cellular fate decisions has informed the development of therapies that modulate these processes in disease [7]. Similarly, insights into DNA repair mechanisms have enabled the development of PARP inhibitors that exploit synthetic lethality in cancer cells with homologous recombination deficiencies [8].

Genomics, transcriptomics, and multi-omics technologies have revolutionised the resolution at which biological systems can be characterised. The decreasing cost and increasing throughput of DNA sequencing have made population-scale genomic studies feasible, enabling the identification of genetic variants associated with disease risk, drug response, and prognosis [9]. Transcriptomic profiling reveals gene expression patterns that distinguish disease subtypes and predict therapeutic response. Proteomic and metabolomic analyses provide functional readouts that complement genomic information, capturing the dynamic state of biological systems [10]. Integration of these multiple omics layers—multi-omics—offers comprehensive molecular portraits that inform precision medicine approaches.

Systems biology and computational modeling provide the frameworks for interpreting complex biological data. By representing biological processes as networks of interacting components, systems approaches enable the prediction of system behaviour under normal and perturbed conditions. Computational models of signalling pathways, metabolic networks, and gene regulatory circuits generate testable hypotheses and guide experimental design [11]. In drug development, systems biology approaches can predict off-target effects and identify optimal combination strategies, reducing the attrition that has historically plagued pharmaceutical development [12].

CRISPR and genome engineering have transformed the ability to manipulate DNA with precision. CRISPR-Cas9 and its derivatives enable gene knockout, knock-in, and base editing across diverse cell types and organisms. In biomedical research, these tools facilitate the creation of disease models, the identification of drug targets through genetic screens, and the development of cell-based therapies [13]. Clinical applications are advancing rapidly, with CRISPR-based therapies showing promise for genetic disorders including sickle cell disease, beta-thalassaemia, and certain forms of inherited blindness [14].

Synthetic biology in therapeutic development represents the application of engineering principles to biological design. Researchers can now construct genetic circuits that sense disease biomarkers and respond by producing therapeutic molecules. CAR-T cells, which are engineered to recognise and eliminate cancer cells, exemplify the power of synthetic biology approaches in medicine [15]. Living therapeutics—engineered bacteria or viruses that deliver therapeutic payloads—are advancing through preclinical and clinical development for applications ranging from cancer to metabolic disorders [16].

Table 1: Biological Innovations Transforming Medical Science

Innovation	Biological Principle	Medical Application	Current Limitations
Next-Generation Sequencing	High-throughput parallel DNA sequencing	Rare disease diagnosis, tumour profiling, prenatal testing	Interpretation of variants of uncertain significance
Multi-Omics Integration	Combined analysis of molecular layers	Biomarker discovery, disease subtyping	Computational complexity; standardisation challenges
Systems Biology Modelling	Network analysis of biological interactions	Drug target identification, combination therapy prediction	Parameter uncertainty; validation requirements
CRISPR-Cas9	RNA-guided DNA cleavage	Gene therapy, functional genomics, disease modelling	Off-target effects; delivery challenges *in vivo*
Base Editing	Chemical conversion of one DNA base to another	Correction of point mutations	Limited target scope; bystander edits
Synthetic Gene Circuits	Engineered genetic regulatory networks	Living therapeutics, biosensors	Complexity; stability; biocontainment
CAR-T Cells	Engineered T-cell receptors	Haematologic malignancies	Solid tumour efficacy; toxicity; manufacturing complexity

3. Clinical Translation and Medical Integration

The translation of biological insights into clinical applications has yielded transformative advances across multiple domains of medicine. These successes demonstrate the power of biological–medical integration to improve patient outcomes.

Precision medicine and personalised therapeutics represent the clinical manifestation of genomic and molecular understanding. Rather than treating all patients with a given diagnosis identically, precision approaches tailor interventions to individual characteristics, including genetic makeup, molecular profiles, and environmental exposures [17]. In oncology, precision medicine has become standard of care, with tumour genotyping guiding selection of targeted therapies that inhibit specific driver mutations. Beyond oncology, precision approaches are emerging in cardiology, neurology, infectious diseases, and other fields [18]. The integration of pharmacogenomics into clinical practice enables selection of drugs and doses based on genetic predictors of metabolism and response, reducing adverse events and improving efficacy [19].

Immunotherapy and targeted therapies have transformed outcomes for patients with previously untreatable malignancies. Immune checkpoint inhibitors, which release the brakes on anti-tumour immune responses, have demonstrated efficacy across multiple cancer types and produced durable responses in a subset of patients [20]. The identification of predictive biomarkers, such as PD-L1 expression and tumour mutational burden, enables selection of patients most likely to benefit. Beyond checkpoint blockade, bispecific antibodies engage immune cells directly against tumour targets, while cancer vaccines aim to stimulate endogenous immune responses against tumour-specific antigens [21].

Regenerative medicine and stem cell applications offer the potential to repair or replace damaged tissues and organs. Induced pluripotent stem cells, generated by reprogramming somatic cells, provide patient-specific platforms for disease modelling, drug screening, and cell therapy development [22]. Directed differentiation protocols have advanced to the point where multiple cell types—including dopamine neurons for Parkinson's disease, pancreatic beta cells for diabetes, and cardiomyocytes for heart failure—can be generated at scale and are entering clinical evaluation [23]. Mesenchymal stem cells, with their immunomodulatory and trophic properties, are being investigated for diverse applications including graft-versus-host disease, inflammatory conditions, and tissue repair [24].

Artificial intelligence and machine learning in clinical decision-making are accelerating the integration of complex biological data into routine practice. AI algorithms now match or exceed human performance in detecting abnormalities in medical images, from mammograms to retinal scans to pathology slides [25]. Beyond imaging, AI systems are being developed to integrate genomic, clinical, and laboratory data into predictive models that estimate disease risk, suggest diagnoses, and recommend treatments. Natural language processing enables extraction of structured information from clinical notes, enriching datasets for research and quality improvement [26]. Foundation models capable of integrating diverse data types—from molecular sequences to clinical narratives—promise to provide comprehensive patient representations that support clinical decisions [27].

Digital health and real-world data integration are transforming the generation and application of clinical evidence. Wearable devices continuously capture physiological parameters, physical activity, and sleep patterns, providing rich datasets that reveal health status and treatment effects in patients' daily lives [28]. Electronic health records, when standardised and linked across institutions, enable large-scale observational studies that complement randomised trials. The integration of real-world data with genomic and molecular information supports pharmacovigilance, comparative effectiveness research, and the refinement of treatment guidelines [29].

Table 2: Integrated Biological–Medical Approaches in Clinical Practice

Approach	Underlying Biology	Clinical Impact	Stage of Implementation
EGFR Inhibitors	Targeting mutant EGFR driving tumour growth	Improved outcomes in EGFR-mutant lung cancer	Standard of care
Immune Checkpoint Inhibitors	Release of inhibitory signals on T cells	Durable responses in multiple cancer types	Standard of care
CAR-T Cell Therapy	Engineered T cells recognising tumour antigens	Curative potential in B-cell malignancies	Approved; expanding indications
PARP Inhibitors	Synthetic lethality in BRCA-deficient tumours	Extended survival in ovarian, breast, pancreatic cancers	Standard of care
CRISPR Gene Editing	Precise correction of disease-causing mutations	Curative potential for sickle cell disease	Approved; expanding
iPSC-Derived Cell Therapies	Patient-specific cells for transplantation	Emerging treatments for Parkinson's, diabetes	Early clinical trials
AI-Integrated Diagnostics	Machine learning analysis of clinical data	Improved accuracy in radiology, pathology	Clinical implementation
Pharmacogenomic Testing	Genetic prediction of drug metabolism and response	Reduced adverse events; improved efficacy	Increasing adoption

4. Infrastructure and Collaborative Ecosystems

Achieving integration of biology and medicine at scale requires robust infrastructure and collaborative ecosystems that connect researchers, clinicians, and patients across institutional and disciplinary boundaries.

Academic–clinical partnerships form the foundational relationship for translational research. Medical centres with strong research programmes create environments in which basic scientists interact directly with clinicians and patients, enabling the bidirectional flow of insights that drives integration [30]. Joint appointments, shared seminar series, and co-located research spaces facilitate the informal interactions that often catalyse collaboration. Academic health sciences centres, which integrate medical schools, teaching hospitals, and research institutes within single organisational structures, represent deliberate attempts to create environments conducive to integration [31].

Public–private research collaborations leverage complementary capabilities from academic and industrial partners. Academic institutions contribute fundamental discovery, methodological expertise, and access to patients, while industry partners bring development capabilities, manufacturing expertise, and regulatory experience. Product development partnerships, structured to share risks and rewards, have proven particularly valuable in neglected disease areas where commercial incentives are limited [32]. The COVID-19 pandemic demonstrated the power of such collaborations, with academic–industry partnerships delivering multiple vaccines in record time [6].

Bioinformatics platforms and data integration systems provide the technical infrastructure for integrating biological and clinical data. Secure research environments, such as Terra and similar platforms, enable researchers to access and analyse genomic, imaging, and clinical data within compliant frameworks [33]. These platforms incorporate tools for data harmonisation, quality control, and analysis, reducing the technical burden on individual researchers and enabling reproducible research. Federated architectures, in which data remain under the control of originating institutions with only analytical queries shared, address privacy concerns while enabling collaborative analysis across multiple sites [34].

Global research consortia enable the scale of data collection and analysis required for many biomedical questions. Rare disease research, which requires aggregation of cases across multiple centres, depends on international collaboration for adequate sample sizes. The Undiagnosed Diseases Network International connects programmes across multiple countries to solve mysterious conditions through combined expertise and data sharing [35]. Similarly, global cancer genomics consortia have assembled cohorts large enough to identify rare driver mutations and characterise tumour heterogeneity across populations [36].

Translational research centers and innovation hubs provide physical and organisational homes for integration. These entities typically bring together diverse expertise—basic scientists, clinical researchers, bioinformaticians, regulatory specialists, and patient advocates—within structures designed to accelerate translation. The National Institutes of Health's Clinical and Translational Science Awards programme has created a network of such centres across the United States, supporting infrastructure for training, pilot funding, and regulatory support [37]. Similar initiatives in Europe, Asia, and elsewhere reflect recognition that deliberate institutional design can accelerate integration.

5. Ethical, Regulatory, and Societal Considerations

The integration of biology and medicine raises profound ethical, regulatory, and societal questions that must be addressed alongside scientific and technical advances.

Bioethical implications of genome editing require careful consideration as technologies advance toward clinical application. Somatic gene editing, which affects only the treated individual, has gained broad acceptance for serious conditions with limited treatment options, as exemplified by regulatory approvals for CRISPR-based therapies in sickle cell disease [14]. Germline editing, which would introduce heritable modifications, remains highly controversial, with international consensus尚未形成 on acceptable boundaries [38]. The potential for enhancement applications, which would use genome editing not to treat disease but to augment normal human capabilities, raises additional ethical questions about equity, consent, and the definition of disease [39].

AI ethics and data privacy in healthcare present urgent challenges requiring attention. As AI systems become more integrated into clinical decision-making, ensuring that these systems are fair, transparent, and accountable becomes essential [40]. Algorithmic bias, arising from training data that do not adequately represent diverse populations, can perpetuate or amplify existing health disparities. The 'black box' nature of some AI models creates tension with requirements for explainability in medical decision-making. Privacy concerns are heightened when AI systems are trained on sensitive health data, requiring robust governance frameworks and technical protections [41].

Regulatory frameworks for advanced therapies are evolving to accommodate novel products that do not fit traditional categories. Gene therapies, cell-based treatments, and combination products challenge regulatory paradigms developed for small molecules and biologics. Adaptive regulatory pathways, which allow iterative evidence generation and conditional approvals, are being implemented to balance timely access with robust safety evaluation [42]. Harmonisation of regulatory requirements across jurisdictions remains incomplete, creating challenges for global development programmes and limiting patient access in some regions [43].

Equity in access to innovative treatments remains a persistent challenge. The high cost of many advanced therapies, driven by development expenses, manufacturing complexity, and small patient populations, limits access even in wealthy countries. In low- and middle-income countries, where the burden of disease is often greatest, access to advanced diagnostics and therapeutics is severely constrained [44]. Ensuring that innovation benefits all populations requires attention to pricing, technology transfer, and health system strengthening, as well as research agendas that address diseases disproportionately affecting disadvantaged populations [45].

Intellectual property and global collaboration require careful balancing. Patent systems incentivise innovation by granting temporary monopolies, but overly broad or restrictive patents can impede further research and limit access. During the COVID-19 pandemic, debates over intellectual property for vaccines and therapeutics highlighted tensions between commercial incentives and global public health needs [46]. Emerging models, including open-source biotechnology and patent pools, offer alternatives that seek to preserve innovation incentives while expanding access [47].

6. Challenges in Achieving Scientific Excellence

Despite substantial progress, significant challenges impede the full integration of biology and medicine and the achievement of scientific excellence.

Fragmentation between basic and clinical research persists across multiple dimensions. Basic scientists and clinicians are often housed in separate institutions, funded by different mechanisms, and rewarded for different outputs. Promotion criteria that value basic discovery publications over translational impact create disincentives for integration. Cultural differences between the cautious, hypothesis-driven approach of basic science and the pragmatic, action-oriented approach of clinical medicine can hinder collaboration [48]. Overcoming these barriers requires deliberate institutional design, including joint appointments, cross-disciplinary training, and funding mechanisms that explicitly support translational teams.

Funding and resource disparities limit the scope and equity of integrated research. Research investment remains heavily concentrated in high-income countries, with low- and middle-income countries accounting for a small fraction of global health research spending [49]. Within countries, funding for basic and clinical research is often siloed, making it difficult to support the continuum from discovery to application. Translational research, which falls between traditional funding categories, can fall through gaps. Essential infrastructure, including biobanks, data platforms, and cohort studies, requires sustained investment that is difficult to maintain in competitive funding environments [50].

Data interoperability barriers impede integration of molecular and clinical datasets. Despite widespread endorsement of FAIR (Findable, Accessible, Interoperable, Reusable) principles, implementation remains inconsistent across institutions and countries. Differences in data models, terminology systems, and consent frameworks make it difficult to combine datasets for research. Electronic health record data, collected for clinical rather than research purposes, require extensive cleaning and harmonisation before they can be used for research. The absence of globally agreed standards for linking genomic and clinical data limits the scale of integrative analyses.

Reproducibility and research integrity challenges undermine confidence in translational findings. Concerns about the reproducibility of preclinical research have been widespread, with studies suggesting that many published findings cannot be replicated. Causes include inadequate experimental design, selective reporting, and pressure for positive results. In translational research, irreproducible findings waste resources, delay progress, and can lead to clinical trials based on unreliable premises. Efforts to improve reproducibility—including preregistration, registered reports, and improved statistical training—are gaining traction but require sustained commitment.

Training the next generation of interdisciplinary scientists is essential but challenging. Traditional graduate and medical education remain largely organised along disciplinary lines, with limited opportunities for cross-training. Clinician–scientist training pathways face particular challenges, as the demands of clinical training and research training compete for time and attention. Programmes that deliberately integrate biological and clinical training, provide mentorship across disciplines, and create protected time for research are essential for developing the workforce needed for integrated science.

7. Future Perspectives

Looking forward, several converging trends will shape the future of integrated biology and medicine over the coming decade.

The convergence of biology, medicine, engineering, and computational sciences will accelerate, blurring traditional disciplinary boundaries. Advances in microfluidics, organ-on-chip technologies, and 3D bioprinting are creating new capabilities for modelling human physiology and disease *in vitro*. Bioelectronic medicine, which uses implantable devices to modulate neural circuits, represents convergence of neuroscience, materials science, and electrical engineering. The integration of these diverse fields will require new educational models and research structures that facilitate cross-disciplinary collaboration.

Integrated omics-driven healthcare systems will enable predictive, preventive, and personalised approaches to medicine. Rather than reacting to established disease, these systems will use multi-omic profiling, environmental monitoring, and behavioural data to identify risk early and intervene before disease develops. Population-scale genomic screening, combined with family history and clinical risk factors, will enable targeted prevention for individuals at elevated genetic risk. Integration of omics data into electronic health records will support clinical decision support that guides treatment selection and dosing based on individual characteristics.

Pandemic preparedness and global health resilience will depend on sustained biological–medical integration. The COVID-19 pandemic demonstrated that viral emergence is not a historical rarity but a recurring threat requiring continuous vigilance. Integrated pathogen surveillance systems, combining genomic epidemiology with clinical and ecological data, will enable earlier detection and characterisation of emerging threats. Platform technologies for vaccine and therapeutic development, designed to be rapidly adapted to novel pathogens, will shorten response times. Strengthened health systems, including diagnostic capacity and clinical trial infrastructure, will ensure that advances benefit all populations.

Sustainable and precision biotechnology will address environmental challenges while creating economic value. Biological production of fuels, chemicals, and materials can reduce dependence on fossil resources and lower environmental impact. Advances in metabolic engineering and synthetic biology are expanding the range of molecules that can be produced sustainably. Integration of biological manufacturing with precision medicine—for example, through patient-specific cell therapies produced on demand—will create new paradigms for treatment delivery.

The vision for the next decade of integrated biomedical science is one of seamless continuity from molecular mechanism to population health. Researchers will move fluidly between laboratory, clinic, and community, armed with tools that enable measurement across scales. Data will flow from research platforms to clinical systems and back, continuously improving both knowledge and care. Achieving this vision requires sustained commitment to the principles of integration, collaboration, and equity that have driven progress to date.

8. Conclusion

This review has examined the integration of biology and medicine as a pathway to scientific excellence, surveying the biological foundations, clinical translations, collaborative infrastructures, and ethical considerations that shape this endeavour.

Major integrative advancements have transformed the landscape of biomedical research and practice. Genomic technologies have revealed the molecular basis of disease with unprecedented resolution. Systems biology approaches enable integration of complex datasets into predictive frameworks. CRISPR and synthetic biology provide powerful tools for manipulating biological systems. In the clinic, precision medicine, immunotherapy, and regenerative medicine demonstrate the power of biologically informed treatment. AI and digital health are accelerating the translation of biological insights into routine care.

The strategic importance of biological–medical convergence lies in its capacity to address the most pressing challenges in human health. Rare genetic diseases, once considered untreatable, are yielding to gene therapy approaches. Cancers that were uniformly fatal now have treatment options producing durable responses. Chronic conditions, from diabetes to neurodegeneration, are being reimagined through the lens of molecular mechanism. The COVID-19 pandemic demonstrated that integrated science, when mobilised around a common threat, can achieve what would have seemed impossible just years earlier.

The outlook for achieving scientific excellence through integration is extraordinarily promising. The technical capabilities at our disposal, the creativity and dedication of the research community, and the growing recognition of science's essential role in addressing global challenges all point toward continued progress. Realising this potential requires deliberate effort: investment in interdisciplinary training, development of collaborative infrastructure, governance frameworks that balance innovation with responsibility, and commitment to equity in access to the benefits of discovery. By working together across traditional boundaries, the global research community can achieve the scientific excellence that integrated biology and medicine promise.

References

1. Zerhouni EA. Translational and clinical science—time for a new vision. N Engl J Med. 2005;353(15):1621-1623.
2. Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299(2):211-213.
3. Dougherty D, Conway PH. The "3T's" road map to transform US health care: the "how" of high-quality care. JAMA. 2008;299(19):2319-2321.
4. Jumper J, Evans R, Pritzel A, *et al*. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589.
5. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
6. Baden LR, El Sahly HM, Essink B, *et al*. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.
7. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667-3683.

8. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152-1158.
9. Green ED, Gunter C, Biesecker LG, *et al*. Strategic vision for improving human health at The Forefront of Genomics. Nature. 2020;586(7831):683-692.
10. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
11. Kitano H. Systems biology: a brief overview. Science. 2002;295(5560):1662-1664.
12. Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nat Biotechnol. 2004;22(10):1253-1259.
13. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258098.
14. Frangoul H, Altshuler D, Cappellini MD, *et al*. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252-260.
15. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73.
16. Weber W, Fussenegger M. Emerging biomedical applications of synthetic biology. Nat Rev Genet. 2012;13(1):21-35.
17. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507-522.
18. Denny JC, Collins FS. Precision medicine in 2030—seven ways to transform healthcare. Cell. 2021;184(6):1415-1419.
19. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-350.
20. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
21. Ott PA, Hu Z, Keskin DB, *et al*. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-221.
22. Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016;17(3):183-193.
23. Pagliuca FW, Millman JR, Gürtler M, *et al*. Generation of functional human pancreatic β cells *in vitro*. Cell. 2014;159(2):428-439.
24. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4:22.
25. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
26. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347-1358.
27. Moor M, Banerjee O, Abad ZSH, *et al*. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259-265.
28. Steinhubl SR, Muse ED, Topol EJ. The emerging field of mobile health. Sci Transl Med. 2015;7(283):283rv3.
29. Sherman RE, Anderson SA, Dal Pan GJ, *et al*. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293-2297.
30. Pober JS, Neuhauser CS, Pober JM. Obstacles facing translational research in academic medical centers. FASEB J. 2001;15(13):2303-2313.
31. Dzau VJ, Yoediono Z, ElLaissi W, Cho AH. Fostering innovation in medicine and health care: what must academic health centers do? Acad Med. 2013;88(10):1424-1429.
32. Moran M, Guzman J, Ropars AL, *et al*. Neglected disease research and development: how much are we really spending? PLoS Med. 2009;6(2): e1000030.
33. Terra: a scalable platform for biomedical research [Internet]. Cambridge (MA): Broad Institute; 2023 [cited 2026 Feb 2[4]]. Available from: https://terra.bio
34. Rieke N, Hancox J, Li W, *et al*. The future of digital health with federated learning. NPJ Digit Med. 2020; 3:119.
35. Taruscio D, Groft SC, Cederroth H, *et al*. Undiagnosed Diseases Network International (UDNI): white paper for global actions to meet patient needs. Mol Genet Metab. 2015;116(4):223-225.
36. The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82-93.
37. Leshner AI, Terry SF, Schultz AM, Liverman CT, editors. The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research. Washington, DC: National Academies Press; 2013.
38. National Academy of Medicine, National Academy of Sciences, Royal Society. Heritable Human Genome Editing. Washington, DC: The National Academies Press; 2020.
39. Juengst ET. Crowdsourcing the moral limits of human gene editing? Hastings Cent Rep. 2017;47(3):15-23.
40. Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. N Engl J Med. 2018;378(11):981-983.
41. Price WN, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37-43.
42. Eichler HG, Baird LG, Barker R, *et al*. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther. 2015;97(3):234-246.
43. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. N Engl J Med. 2012;366(9):848-855.
44. Moon S, Mariat S, Kamae I, Pedersen HB. Defining the concept of fair pricing for medicines. BMJ. 2020;368: l4726.
45. World Health Organization. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. Geneva: WHO; 2011.
46. Gaviria M, Kilic B. A network analysis of COVID-19 mRNA vaccine patents. Nat Biotechnol. 2021;39(5):546-548.

47. Medicines Patent Pool. Annual Report 2023. Geneva: MPP; 2024.
48. Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840-842.
49. Global Forum for Health Research. Monitoring Financial Flows for Health Research. Geneva: Global Forum for Health Research; 2022.
50. Global Biodata Coalition. Working Cooperatively for Global Biodata Resource Sustainability: A White Paper. Global Biodata Coalition; 2025. Available from: https://globalbiodata.org

How to Cite This Article

Bennett SL. Integrating biology and medicine for scientific excellence. International Journal of Biological and Biomedical Research. 2026;2(2):14–21.